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Abstract The Fas/FasL system plays an important role in
apoptosis, the inﬂammatory response and gliosis in a
variety of neurologic disorders. A better understanding of
these mechanisms could lead to effective therapeutic
strategies following spinal cord injury (SCI). We explored
these mechanisms by examining molecular changes in
postmortem human spinal cord tissue from cases with acute
and chronic SCI. Complementary studies were conducted
using the in vivo Fejota
TM clip compression model of SCI
in Fas-deﬁcient B6.MRL-Fas-lpr (lpr) and wild-type (Wt)
mice to test Fas-mediated apoptosis, inﬂammation, gliosis
and axonal degeneration by immunohistochemistry,
Western blotting, gelatin zymography and ELISA with
Mouse 32-plex cytokine/chemokine panel bead immuno-
assay. We report novel evidence that shows that Fas-
mediated apoptosis of neurons and oligodendrocytes
occurred in the injury epicenter in all cases of acute and
subacute SCI and not in chronic SCI or in control cases.
We also found signiﬁcantly reduced apoptosis, expression
of GFAP, NF-jB, p-IKappaB and iba1, increased number
of CD4 positive T cells and MMP2 expression and reduced
neurological dysfunction in lpr mice when compared with
Wt mice after SCI. We found dramatically reduced
inﬂammation and cytokines and chemokine expression in
B6.MRL-Fas-lpr mice compared to Wt mice after SCI. In
conclusion, we report multiple lines of evidence that Fas/
FasL activation plays a pivotal role in mediating apoptosis,
the inﬂammatory response and neurodegeneration after
SCI, providing a compelling rationale for therapeutically
targeting Fas in human SCI.
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Introduction
Spinal cord injury (SCI) causes the shearing of cell mem-
branesandaxons,disruptionoftheblood–spinalcordbarrier,
cell death, immune cell transmigration, and myelin degra-
dation [4–7, 9, 34]. It also triggers a cascade of secondary
damage including vascular permeability, inﬁltration of
peripheral inﬂammatory cells, activation of astrocytes and
microglia, release of pro-inﬂammatory mediators, demye-
lination and axonal damage [37] which progressively
destroys an increasing amount of tissue adjacent to the pri-
mary lesion [5, 14, 27, 38]. The death receptor Fas and its
speciﬁcligand(FasL)havegainedwidespreadrecognitionas
anapoptoticmediator[11,12,15–17,20,32,33]forinducing
inﬂammation by release of pro-inﬂammatory cytokines [26,
39],causingthemigrationofneutrophilsandmacrophagesto
injury site [17, 31] and being involved in T cell proliferation
[28] following SCI as well as maintaining the immune sup-
pressed status in the normal brain. Fas deﬁciency [11, 44,
45], competitive inhibition of Fas activation, or neutraliza-
tion of FasL with an anti-FasL antibody can promote
neurobehavioral recovery in animal models of stroke, SCI
[1, 16, 45] and cervical spondylotic myelopathy [46].
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inﬂammatory cells, creating an inﬂammatory response that
facilitates recovery of locomotor function after SCI [31]. A
better understanding of these mechanisms could lead to
effective therapeutic strategies following SCI.
In this study, we investigated, for the ﬁrst time, the
importance of the Fas/FasL system in the regulation of
neuronal and glial apoptosis, inﬂammatory cell inﬁltration,
gliosis and axonal regeneration following human SCI. We
examined the molecular changes in postmortem human
spinal cord tissue after acute, subacute and chronic SCI. To
provide a mechanistic basis for these observations, com-
plementary investigations were undertaken in a clinically
relevant murine model of SCI using mutant mice deﬁcient
in Fas expression. Our results clarify the importance of Fas/
FasL in the pathobiology of human SCI thus providing a
strong case for targeting Fas therapeutically in this devas-
tating clinical condition.
Materials and methods
Human SCI
Sections of parafﬁn tissue with 5 lm thickness were
retrieved from the Spinal Cord Tissue Bank (Table 1:1 6
cases of SCI and 6 controls) in the pathology department,
University Health Network, Toronto, Canada for Hema-
toxylin and Eosin and Luxol Fast Blue (H&E/LFB)
staining and immunohistochemistry.
Immunohistochemical analysis in human SCI
After being deparafﬁnized, sections were treated with
microwave in 10 mM citrate buffer, 0.3% H2O2, avidin
solution and blocked with 1% BSA and 5% nonfat milk
with 0.3% Triton X-100 for 1 h. The following primary
antibodies were used in this study: anti-Fas and anti-FasL
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA) for
cell death receptor, activated caspase-3 (1:200, Cell Sig-
naling Technology, Beverly, MA); activated caspase-9 and
caspase-7 (1:150; 1:1,500 Nov Littleton, CO 80160, USA)
for apoptosis, anti-PG-M1 (CD68 for phagocytic macro-
phages of microglial and monocytic: 1:50, Dako, Glostrup,
Denmark), anti-ionized calcium binding adaptor molecule
1 (Iba1) for ramiﬁed and activated microglia (I:300, Wako
pure Chemical Industries, Lid); anti-CD3 (1:200, Dako,
Denmark) for the human mature T lymphocytes; anti-
CD45 (1:500, BD) for B lymphocytes, anti-MPO (1:50,
Dako, Denmark) for oxidative reactivity, and MMP-9
(1:100, Chemicon), a pro-inﬂammatory protease, in
blocking solution overnight at 4C. Following extensive
Table 1 Summary of the
clinical and neurological data in
the human SCI and control
cases
Case Age Sex Group Time between
injury and death
Level of
injury
Cause of
injury
1 73 M Acute 2 weeks C1-2 Fall
2 86 M Acute 3 weeks C1-2 Fall
3 37 M Acute 4 weeks C4-5 Fall
4 82 M Subacute 5 weeks C5-6 Sports injury
5 68 M Subacute 5 weeks C7 MVA
6 29 M Subacute 7 weeks T12 Fall
7 68 F Subacute 2 months T5 Fall
8 67 M Subacute 3.5 months C2-3 Fall
9 43 F Subacute 3.5 months C5-6 MVA
10 66 M Chronic 6 months C5-6 Fall
11 31 F Chronic 8 months C2-3 MVA
12 19 M Chronic 2 years C4/5 Sports injury
13 65 M Chronic 3.5 years C1-2 MVA
14 69 M Chronic 15 years C6/7 Diving accident
15 42 M Chronic 24 years C3/4 MVA
16 45 M Chronic 24 years C5/6 Sports injury
17 43 F Control N/A N/A N/A
18 36.8 F Control N/A N/A N/A
19 41.7 F Control N/A N/A N/A
20 81.5 M Control N/A N/A N/A
21 55 F Control N/A N/A N/A
22 44 M Control N/A N/A N/A
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123rinsing in 0.1 M PBS, sections were incubated in biotin-
ylated goat anti-mouse or anti-rabbit antibody (diluted
1:200, Vector Laboratories CA, USA) for 1 h at room
temperature. After incubation with the biotinylated sec-
ondary antibody, the avidin–biotin complex (ABC;
VECTASTAIN
 ABC reagent prepared in advance as
described in the kit instructions) and diaminobenzidine
(DAB; DAB Peroxidase Substrate Kit, Vector Laborato-
ries) were applied to the sections for visualization of the
reaction product. Sections from six nonSCI patients (age-
matched) were used as normal controls. For negative
controls, the primary antibody was omitted or incubated
with isotype-matched antibodies (1:100–1:10,000; IgG).
Analysis of apoptosis for Human SCI
Spinal cord sections were processed for TUNEL labeling
(ApopTag
) plus a peroxidase in situ apoptosis detection
kit (Chemicon Biotechnology Inc, Temecula, CA), as
previously described [13].
In vivo spinal cord injury
SCI was performed by the Fejota
TM clip compression
technique at T5/6 [24, 25] with 8.3 g clip for 1 min in
8-week-old female wild-type (Wt) and B6.MRL-Fas-lpr
(lpr) mice bought from Jackson Laboratory, Bar Harbor,
Maine, as previously described. All protocols were in
accordance with the Canadian Council of Animal Care
policies and were approved by the animal care committee
of the University Health Network.
Biotinylated dextran amine (BDA) tracing
of the corticospinal tract (CST) and BDA staining
To trace the corticospinal tract, Wt and lpr mice (n = 4/
group) were anesthetized and had their fur removed by
shavingafter8 weekspost-injury.Thescalpwasincisedand
the skull overlying the sensorimotor cortex was carefully
removed with a dental drill. BDA (molecular weight of
10,000)with10%inDH2O(MolecularProbes,Eugene,OR)
was injected into right sensorimotor cortex with a total of
four sites using a 10 ll Hamilton microsyringe tipped with a
pulled glass micropipette. Coordinates were 1.0 lateral,
0.5 mm deep to the cortical surface, and ?0.5, -0.2, -0.7,
and 1.0 mm with respect to Bregma. After the injections
were completed, the skin overlying the skull was sutured
with 4-0 silk as previously described [13]. Two weeks later,
all the animals were deeply anesthetized and then were
perfusedtranscardiallywithPBSand4%paraformaldehyde.
The spinal cord was post-ﬁxed overnight and embedded
within Tissue-Tek
 optimal cutting temperature compound
(O.C.T; Sakura Finetek USA, Inc., Torrance, CA). The
longitudinalsectionsof20 lmwerecutandwashedtwicein
0.05 M TBS containing 0.5% Triton X-100. After two
washes in TBS, the sections were incubated with Texas red-
conjugated streptavidin to visualize BDA containing corti-
cospinal axons for 30 min. The sections were washed and
coverslipped with glycerol containing DAPI.
Immunohistochemical analysis for mice
Wt and lpr mice were perfused transcardially with 4%
paraformaldehyde solution. Spinal cord samples of 1 cm
length centered at the injury site were dissected, post-ﬁxed
and embedded. Transverse sections of 14 lm were cut,
blocked in a blocking solution (0.3% Triton X-100, 5%
milk and 1% BSA in PBS) and incubated with GFAP, F4/
80, CD4, Iba1, MBP, NF200 and MAP2 antibodies. The
slides were incubated with ﬂuorescent Alexa 594 or 488
anti-mouse, anti-rabbit or anti-rat secondary antibodies
(1:200; Sigma-Aldrich) for 1 h. Staining speciﬁcity was
determined both by omitting the primary antibody and by
competing the primary antibody with its corresponding
peptide prior to incubation.
Western Blotting in Wt and lpr mice
Spinal cord proteins from Wt and lpr mice (n = 11 per
group for sham, 3, 14 days, n = 5 for 1, 7, 70 days) were
individually homogenized in a RIPE buffer (Themo Fisher
Scientiﬁc, Attawa, Canada) at 4C, resolved (20–50 lg per
lane) in a 12% or 7.5% SDS-polyacrylamide gel at 200 V
and transferred to a nitrocellulose membrane. Membranes
were blocked with 5% nonfat milk for 1 h and incubated
with (1) NF200 (1:1,000; Sigma); (2) MAP2 (1:200,
Sigma); (3) b-III tubulin (1:400, Chemicon); (4) caspase-3
(Cell Signaling Technology); (5) GFAP (1:1,000; Chem-
icon); (6) Iba1 antibody (1:400, Wako Chemicals USA,
Inc); (7) CNPase (1:400, Chemicon); (8) NF-jB (1:400,
Chemicon) and (9) Phosphorylation of IKappaB alpha
(p-IKappaB) (1:1,000; Cell Signaling Technology) anti-
bodies. Membranes were incubated with mouse (1:4,000)
or rabbit (1:2,000) secondary antibodies conjugated to
horseradish peroxidase. Reaction products were visualized
using an ECL Western Blot Detection kit (Amersham
Biosciences Inc) and Gel Pro analysis software (Media
Cybernetice, Silver Spring, MD) to quantify the amount of
protein. Densitometric values were normalized to those of
ß-actin (1:400; Sigma).
Multiplex analysis of cytokines and chemokines protein
expression in mice
A total of 80 ll per sample of sham controls, and 3, 14 and
70 days (n = 7 per group) after SCI in MicroCon
Acta Neuropathol (2011) 122:747–761 749
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company using the Mouse 32-plex cytokine/chemokine
panel Bead Immunoassay. The protein concentrations of 32
chemokines/cytokines were quantiﬁed and then analyzed
using repeated measures ANOVA and t tests using the
SPSS SigmaStat 3.0 statistical package (Aspire Software
International, Leesburg, VA).
Zymography
Zymogram gels consisted of 7.5% polyacrylamide (native)
gel polymerized together with gelatin (1 mg/ml). After
electrophoresis, the gels were washed twice with 2.5%
Triton X-100 and incubated with substrate buffer (50 mM
Tris, 5 mM CaCl2, pH 7.5) at 37C for 24 h. The zymo-
gram is subsequently stained (commonly with coomassie
brilliant blue), and areas of digestion appear as clear bands
against a darkly stained background where the substrate
has been degraded by the enzyme. Gelatinolytic of MMPs
activities were detected as transparent bands on the blue
background and quantiﬁed using Gel Pro analysis software
(Media Cybernetice, Silver Spring, MD).
Behavioral tests
All behavioral tests were performed by two independent
observers in a double-blind manner weekly for 8 weeks
after SCI and assessed using the Basso Mouse locomotor
rating Scale (BMS) [3].
Cell quantiﬁcation
All digital images were captured, in a double-blind manner,
fromfourrandomﬁeldspersectionintheinjuredepicenterof
the cross-sections in human SCI and control cases using a
NikonEclipseE800lightmicroscopeandinWtandlprmice
using a Zeiss LSM 510 META confocal laser scanning
ﬂuorescence microscope. The images were taken at 209
magniﬁcation for CD68, TUNEL, F4/80 and CD4 positive
cell counting. We counted digital images of CD68, TUNEL
andF4/80positivecellsusingImageJsoftware(developedat
theNationalInstituteofHealth,Bethesda,MD).Valuesfrom
fourrandomﬁeldswereaveragedtoasinglevaluepercaseor
per animal. The results were expressed as the number of
CD68, TUNEL and F4/80 positive cells.
Statistical analysis
Signiﬁcant differences in cell counts were analyzed using
repeated measures ANOVA and t test using the SPSS
statistical package as before. All data are expressed as
mean ± SD. The criterion for signiﬁcance was set at
p\0.05.
Results
The characteristics of the human SCI subjects are outlined
in Table 1. The age range was 19–86 and the time between
injury and death ranged from 2 weeks to 24 years.
Fas-mediated inﬂammatory response after human SCI
To determine the role of FasL in the modulation of immune
reactions involving inﬂammation, we examined the inﬂam-
matory response following human SCI using immuno-
histochemistry with CD68. We observed a moderate to
marked increase in the number of CD68 positive microglia/
macrophages, which showed features typical of activated
microglia/macrophages including small, round shapes with
short processes, occurring at 2 weeks (Fig. 1b, k), 3 weeks,
4 weeks (acute SCI: 2–4 weeks as see Table 1) and
3.5 months (subacute: 5 weeks to 3.5 months) (Fig. 1c–e)
afterSCI.However,thenumberofCD68positivemicroglia/
macrophages was decreased at 6 months (Fig. 1f) and
8 months (chronic SCI: over 6 months) (Fig. 1g) post-SCI
when compared to 3 weeks (Fig. 1c), 4 weeks (Fig. 1d) and
3.5 months(Fig. 1e).Therewasasmallnumberofactivated
microglia and many cells with ramiﬁed morphology in the
epicenter of the SCI at 2 years and 17 years (Fig. 1h, i) after
SCI and control spinal cords (Fig. 1a, j). The number of
CD68 positive microglia/macrophages was signiﬁcantly
greater in the compressed epicenter of SCI when compared
with normal spinal cords (p = 0.003, Fig. 1l). As illustrated
in Fig. 2b, we found many MMP9 positive cells in the epi-
centers of spinal cord in acute and subacute SCI but not in
control or chronic SCI cases. Moreover, we observed
numerous cells which expressedMPO(Fig. 2c), a marker of
neutrophils, distributed in the spinal cord parenchyma.
Increased lymphocytic inﬁltration in the injured
human SCI
There was a scattered distribution of CD3 and CD45
positive cells in blood vessels in control and chronic SCI
cases. Moreover, in contrast to control cases, there were
also numerous CD45 and CD3 positive cells (Fig. 2d, e)
randomly distributed in the spinal cord epicenter paren-
chyma following acute and subacute SCI.
Apoptosis after human SCI
In investigating whether SCI-induced apoptosis occurred
by activated caspase-3 and TUNEL as complementary
markers of apoptosis (Fig. 3), we observed that most cells
which were positive for activated caspase-3 (Fig. 3b, c) or
TUNEL (Fig. 3k, l) were randomly distributed in the
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following SCI but not in control cases or following
chronic SCI (Fig. 3a, j) and caudal regions of SCI spinal
cords. We found activated caspase-3 positive oligoden-
drocytes (Fig. 3d), neurons, neutrophils (Fig. 3e) and
microglia/macrophages (Fig. 3f) in the injured epicenter
of SCI. To look speciﬁcally at the apoptotic pathway, we
examined the involvement of mitochondria by assessing
the activation of caspase-9 and caspase-7 which are
downstream targets of this pathway. We found that acti-
vated caspase-9 (Fig. 3g) and caspase-7 (Fig. 3h) were
expressed on neurons and glial cells after acute SCI. No
activated caspase-9 and caspase-7 positive cells were seen
in control or chronic SCI cases. The quantiﬁcation of
apoptotic cells showed a signiﬁcant increase in the
number of TUNEL-positive cells in the injured epicenter
of SCI when compared with chronic SCI and control
cases (P\0.05) (Fig. 3i).
Fas/FasL accumulation in the epicenter of human SCI
lesions
To test whether spinal cord injury induces Fas/FasL
accumulation, we performed immunohistochemistry with
Fig. 1 Accumulation of microglia/macrophages in human SCI.
CD68-positive cells in normal control spinal cord (a, j). There were
numerous CD68-positive microglia/macrophages in the epicenter of
the injured spinal cord at acute (b and k 2 weeks, c 3 weeks,
d 4 weeks) and subacute SCI (e 3.5 months) time points. There was a
signiﬁcant increase in the number of CD68 positive microglia/
macrophages (l) in the epicenter of acute SCI and subacute SCI when
compared to control (a) and chronic SCI (f 6 months, g 8 months,
h 2 years and i 17 years)
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FasL positive cells in control spinal cords (Fig. 4a, d) and
in chronic SCI. However, we observed a lot of Fas or FasL
positive glial cells (Fig. 4b, e) and neurons (Fig. 4c, f) in
injured epicenters in acute and subacute SCI when com-
pared with control cases and chronic SCI. Using double
staining with Fas or FasL antibodies and cell-speciﬁc
markers, Fas or FasL immunoreactivity was expressed in
neurons, astrocytes and microglia/macrophages in the
injured epicenter after SCI.
Fas/FasL-mediated apoptosis and inﬂammation
in human SCI
To conﬁrm that Fas/FasL expression is associated with
apoptotic cell death and inﬂammation, we ﬁrst performed
double-labeling activated caspase-3 with anti-Fas or anti-
FasL antibodies. We identiﬁed the Fas or FasL positive-
activated caspase-3 (Fig. 4g, h) in the injured epicenter
after SCI. Examining Fas/FasL-mediated inﬂammation
using double-labeling CD68 and MPO with Fas and FasL
antibodies, we found Fas or FasL positive macrophages
(Fig. 4i, j), astrocytes (Fig. 4k) and neutrophils (Fig. 4l) in
the injured epicenter after acute and subacute SCI.
Fas-deﬁcient mice exhibit reduced GFAP expression
after SCI
To conﬁrm the Fas/FasL-mediated inﬂammation as seen in
human SCI, we used the Fejota
TM clip compression model
of SCI in lpr and Wt mice to test Fas-mediated apoptosis,
inﬂammation, gliosis and axonal degeneration. Using
immunohistochemistry and Western blotting with GFAP
antibody, we observed an increase in GFAP expression
after SCI in both lpr mice (Fig. 5c) and Wt mice (Fig. 5b)
at 7–70 days post-SCI but not in sham controls (Fig. 5a).
However, lpr mice showed a marked attenuation in the
expression of GFAP at 3 (p = 0.003) and 14 (p = 0.012)
days post-SCI compared with Wt mice as determined by
Western blot analysis (Fig. 5d).
Fas-deﬁcient mice exhibit reduced inﬂammatory cell
inﬁltration after SCI
To conﬁrm the Fas/FasL-mediated inﬂammation as seen
in human SCI, we used immunostaining with microglia/
macrophages (Iba1) and macrophages (F4/80) antibodies
following SCI in lpr and Wt mice. We found many Iba1
positive cells with larger, rounded, and short processes,
typical of activated macrophages in the degenerated white
matter of spinal cords, after SCI from 7 to 70 days in
both lpr and Wt mice when compared to sham control
(Fig. 5e). There was a signiﬁcant increase in the number
of F4/80 positive macrophages at the injured epicenter of
SCI in lpr mice when compared with the Wt mice at 3
(p = 0.003), 7 (p = 0.012) and 70 days post-SCI (not
shown). Of note, lpr mice had signiﬁcantly decreased
numbers of short ramiﬁed microglia surrounding the
injured epicenter when compared with Wt mice in sagittal
section using immunostaining with Iba1 antibody (not
Fig. 2 Increased MMP9, MPO and lymphocytic positive cells after
human SCI. There are numerous MMP9 positive cells (b), MPO
(c) positive neutrophils, CD45-positive B lymphocytes (d) and CD3
positive T lymphocytes (e) in the epicenter of the spinal cord after
SCI when compared to the control case (a)
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NF-jB and p-IKappaB antibodies showed that there was a
signiﬁcant decrease in the level of Iba1 expression at 3
(p = 0.043) and 7 (p = 0.004) days (Fig. 5h, j), NF-jB
expression at 3 (p = 0.002) and 14 days (p = 0.019)
(Fig. 5h, k) and p-IKappaB expression (which plays a key
role in regulating the immune response to infection) at 7
(p = 0.024), 14 and 70 days (p = 0.004) (Fig. 5i, l) in lpr
mice when compared with the Wt mice after SCI,
respectively. Moreover, there was signiﬁcant elevation of
MMP2 activation (Fig. 5m, n) in lpr mice when compared
with the Wt mice at 7 days post-SCI but not MMP9
activation.
Fas-deﬁcient mice exhibit increased CD4 positive
lymphocytes after SCI
Given that Fas/FasL-mediated apoptosis appears to be
closely linked with the immune response to trauma, we
analyzed the expression of immune cells. Of note, we
observed that there was a signiﬁcantly increased number of
CD4 positive lymphocytes present in the injured spinal
Fig. 3 Apoptosis in human acute SCI. Caspase-3 positive cells
(b and c) were observed after acute SCI but not in control spinal cords
(a) or chronic SCI. Oligodendrocytes (d APC), neutrophils (e MPO)
and microglia/macrophages (f CD68) undergo apoptosis after acute
SCI. We also found that activated caspase-9 (g) and caspase-7
(h) were expressed on neurons after acute SCI. There was a
signiﬁcant increase in the number of TUNEL-positive cells at the
epicenter after SCI when compared with control cases and chronic
SCI (i). Many TUNEL-positive cells were observed in the injury
epicenter at 2 weeks (k) and 3.5 months (l) after SCI. No activated
caspase-3 and TUNEL-positive cells were seen in control cases (a, j)
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mice (Fig. 6a–c).
Fas-deﬁcient mice exhibit increased the levels
of anti-inﬂammatory cytokines and reduced
pro-inﬂammatory cytokines after SCI
There is a correspondence between the extent of microglia/
macrophage reactivity and the elevation of inﬂammatory
cytokines inducing lymphocyte proliferation and neuroin-
ﬂammatory response after SCI. Using ELISA with Mouse
32-plex cytokine/chemokine panel bead immunoassay, we
found signiﬁcantly increased the levels of anti-inﬂamma-
tory cytokine IL-10 and IL-7 (Fig. 6d, e) expression at
3 days and reduced levels of pro-inﬂammatory cytokines
IL-1alpha, IFN gamma and IL-15 (Fig. 6g–i) at 14 days
and IL-6 at 3 days (Fig. 6j) after SCI in lpr mice when
compared with Wt mice. We also found a signiﬁcant
increase in the levels of pro-inﬂammatory cytockines of
IL-1alpha, IL-15 and IL-12p40 at 14 days (Fig. 6g, i, k)
and IL-6 at 3 days (Fig. 6j) after SCI when compared with
sham control in Wt mice.
Fig. 4 Fas/FasL-mediated apoptosis and inﬂammation in human SCI.
We found few Fas (a) and FasL (b) positive glial cells in control
spinal cords. An increase in the number of Fas (d) and FasL
(e) positive glial and Fas (c) and FasL (f) positive neurons was seen at
2 weeks following SCI. There is co-localization of Fas with activated
caspase-3 (g), FasL with activated caspase-3 (h), Fas with microglia/
macrophages (i), FasL with microglia/macrophages (j), FasL with
astrocytes (k), and FasL with neutrophils (l) in the injured epicenter at
2 weeks after acute SCI
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after SCI
The chemokines are involved in a wide variety of processes
including acute and chronic types of inﬂammation and infec-
tious diseases. To conﬁrm Fas/FasL-mediated inﬂammation
involved chemokines after SCI, we used an ELISA with
Mouse32-plexcytokine/chemokinepanelbeadimmunoassay
andfoundasigniﬁcantincreaseinthelevelsofchemokinesof
MCP-1 (monocyte chemoattractant protein-1: Fig. 7a),
Eotaxin (Fig. 7b), RANTES/CCL5 (regulated upon activa-
tion, normal T-cell expressed and secreted: Fig. 7c), MIG
(Monokine induced by IFN gamma (Fig. 7d), MIP-1a ˛
(macrophage inﬂammatory protein-1a ˛: Fig. 7e) at 14 days
Fig. 5 Fas-deﬁcient mice exhibited reduced glial scar formation and
inﬂammation following SCI. lpr mice showed a signiﬁcant decrease
in the expression of GFAP at 7 days as illustrated by immunostaining
[a Wt (sham); b Wt and c lpr] and by Western blot analysis (d) when
compared to Wt mice at 3 days and 7 days (p = 0.001). We also
found a signiﬁcant decrease in the number of Iba1 positive microglia
as illustrated by immunostaining [e sham (Wt), f Wt, g lpr] and
densitometry of Iba1 expression by Western blotting in lpr mice
relative to Wt mice (h, j). Furthermore, there is a signiﬁcant decrease
in NF-jB( h, k) and p-IKappaB (i, l) expression and an increase in
MMP2 expression (m, n)i nlpr mice relative to Wt mice following
SCI
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stimulating factor: Fig. 7g) from 3 or 14 to 70 days post-SCI
when compared with sham controlinWt mice. Moreover, we
found signiﬁcantly reduced levels of chemokines MCP-1 and
Eotaxin (Fig. 7a, b) at 14 days after SCI in lpr mice when
compared with Wt mice after SCI. We did not ﬁnd any dif-
ferencesinG-CSF,IL-1ß,Il-2,IL-9andVEGFbetweenlprand
Wt mice after SCI (not shown). Moreover, the standard range
was exceeded for IL-3, Il-4, IL-5, IL-12p70, ILX, TNF-a ˛,and
GM-CSF (not shown) following SCI in both lpr and Wt mice.
Changes for BDA labeling CST
To investigate Fas-mediated inﬂammation in axon regener-
ation, we examined the long-term outcome andpathology of
spinal-injured animals in lpr and Wt mice. Sagittal sections
containing the lesion revealed prominent BDA labeling of
the main CST in the dorsal column and extensive collaterals
in the gray matter rostral to the injury (Fig. 8a, b). BDA-
labeled axons ended just rostral to the injury site in lpr mice
but ended further from the injured site in Wt mice.
Western blotting results
There was signiﬁcantly increased b-III tubulin and NF200
expression at 3, 14 and 70 days post-SCI (Fig. 8c–e) and
elevation of axonal growth-associated protein MMP2
expression at 7 and 14 days (Fig. 5i, j) post-SCI. Upregu-
lation with chemokine (KC) expression (Fig. 8f, g) was
associated with axonal growth at 14 and 70 days post-SCI
Fig. 6 IncreasednumberofCD4positivecellsandchangesofcytokines
in lpr mice after SCI. There is a signiﬁcantly increased number of CD4
positivelymphocytesintheinjuredspinalcordat7and14 daysafterSCI
in lpr mice (b, c)r e l a t i v et oW tm i c e( a, c). We observed a signiﬁcant
increase of anti-inﬂammatory cytokines IL-10 (d) and IL-7 (e) at 3 days
in lpr mice when compared with Wt mice after SCI. We furthermore
found a signiﬁcant reduction in the amount of pro-inﬂammatory
cytokines of IL-1alpha (g), IFN gamma (h) and IL15 (i)a t1 4d a y sa n d
IL-6(j)at3 daysinlprmicewhencomparedtoWtmiceafterSCI,butdid
not see a reduction in IL-13 (f). However, we also found a signiﬁcant
increaseinthe amountofcytokinesIL-12(p-10) (k)at3da ysi nlpr mice
when compared to Wt mice after SCI
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also no signiﬁcant differences in MAP2, CNPase and MBP
expression (Fig. 8i, j) as assessed by Western blotting with
MAP2, CNPase and MBP antibodies.
Fas-deﬁcient mice exhibit decreased neurological
dysfunction after SCI
To determine if the increased b-III tubulin and NF200
expression in the lpr mice would support improved func-
tional recovery, the mice were tested using the BMS open
ﬁeld locomotor test and compared with Wt mice. A normal
BMS score for mice, before injury, is 9. The locomotor
performance of the lpr mice was consistently better than
that of the Wt mice (p = 0.001). These signiﬁcant differ-
ences were retained until the end point of evaluation in
BMS scores of both groups at 70 days post-SCI (Fig. 8k).
The average score of the lpr mice at 70 days was
3.087 ± 0.191, while the average score of the Wt mice
over the same time points was 1.583 ± 0.204.
Discussion
We report novel evidence showing a role for Fas/FasL in
apoptosis of neurons and oligodendrocytes and the
inﬂammatory response in human SCI. To provide a
mechanistic basis for these ﬁndings, we determined that
Fas-deﬁcient mice with SCI exhibit a signiﬁcant reduction
in the inﬁltration of inﬂammatory cells (microglia/macro-
phages), reduction in the level of GFAP and p-IKappaB
expression and release of cytokines and chemokines as
compared with Wt controls. Importantly, recovery of
locomotor function is facilitated in Fas-deﬁcient mice
when compared with Wt mice after SCI. These data
strongly suggest that targeting the Fas pathway is an
attractive therapeutic target following SCI.
A growing body of evidence indicates that Fas-mediated
neuronal and oligodendrocyte apoptosis and inﬂammation
contribute to demyelination and Wallerian degeneration,
and thereby affect neuronal function and survival, in the
pathobiology of SCI [1, 2, 5, 12, 16, 19, 41, 44]. We and
others have shown that neuronal, oligodendrocyte and
microglia apoptosis, through activation of the Fas death
receptor pathway is a key event [12, 15, 16, 43, 44, 47]
following SCI in animal models. Davis reported that SCI
resulted in FasL and Fas translocation into membrane raft
microdomains where Fas associates with the adaptor pro-
teins Fas-associated death domain, caspase-8, cellular FLIP
long form, and caspase-3, forming a death-inducing sig-
naling complex [15]. Fas deﬁciency [11, 44], the
application of soluble Fas receptor [1] and neutralization of
Fig. 7 Changes in levels of chemokines following SCI. We observed
an increase in the chemokines MCP-1(a), Eotaxin (b), RANTES (c),
MIG (d), MIP-1a ˛ eotaxin (e), MIP-2 (f) and M-CSF (g) following SCI
in both Wt and lpr mice. We found a signiﬁcant reduction in MCP-1
and Eotaxin expression only at 14 days in lpr mice when compared to
Wt mice after SCI
Acta Neuropathol (2011) 122:747–761 757
123endogenous FasL [16, 45] have decreased apoptosis and
improved functional recovery. The increased expression of
Fas and FasL after SCI [12, 16, 44, 47] results in the
continued activation of microglia and the inﬂammatory
response to injury, inducing a cascade of apoptotic cell
death [4], contributing to demyelination and Wallerian
degeneration and thereby affecting neuronal function and
survival. Consistent with previous ﬁndings that oligoden-
drocyte and neuronal apoptosis was detected in Wallerian
degenerating areas at 6 h to 3 weeks post-injury in animal
models and in a lesion epicenter from 0–3.5 months fol-
lowing humans SCI, we demonstrated an increased
caspase-3, 7 and 9 activation, TUNEL, Fas and FasL
positive cells in injured epicenter following human acute
and subacute SCI but not in chronic SCI or in control cases.
We report new evidence that conﬁrms Fas/FasL-mediated
apoptosis and which shows Fas/FasL co-localization with
activated caspase-3 in the injured epicenter of SCI sug-
gesting Fas-mediated apoptosis plays an important role in
neuronal degeneration following SCI. Thus these data
Fig. 8 Fas-deﬁcient mice show reduced axonal degeneration and
neurological dysfunction following SCI. BDA-labeled CST axons
ended just rostral to the injury site in lpr mice (a) but further away in
relation to the injured site in Wt mice (b). We found elevated
expression of NF200 (c), b-III tubulin (d, e) and growth-associated
chemokines (f P-10, g KC, and h LIF) in lpr mice when compared
with Wt mice. However, we no found difference in CNPase (i) and
MAP2 (j) expression as assessed by Western blotting with CNPase
and MAP2 antibodies. There is a signiﬁcant difference in BMS scale
(k) between lpr mice and Wt mice
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123provide evidence that the functional neurological deﬁcits
after SCI are associated with loss of neurons, oligoden-
drocytes, and demyelination.
SCI elicits an inﬂammatory response involving resident
microglia and inﬁltration of neutrophils, monocytes/mac-
rophages, and lymphocytes into the lesion from the
systemic immune system [22, 35]. Activated microglia/
macrophages were found in the spinal cord from 5 days to
4 months [10] and a year after human SCI [21]. We pro-
duced similar results which show that activated microglia/
macrophages were the predominant inﬂammatory cell type
in all cases of SCI from 2 weeks to 6 months at injured
epicenter but not in rostral and caudal regions following
human SCI. We also found co-localization of Fas/FasL on
macrophages, neutrophils and astrocytes in the epicenter of
SCI suggesting Fas-mediated inﬂammation following
human SCI.
The inﬂammatory response may be beneﬁcial, reﬂecting
the role of inﬂammation as a host defense response to
injury and promoting the regeneration of surviving neurons
or it may release toxic factors that amplify tissue damage
which can lead to poor functional recovery following SCI
[37]. Letellier et al. [31] reported that lack of FasL on CNS
resident neural cells reduces the initial inﬁltration of
inﬂammatory cells, creating an inﬂammatory response after
SCI. However, the molecular mechanism by which Fas
induces inﬂammation has remained elusive. To further
conﬁrm Fas/FasL-mediated apoptosis and inﬂammation
occurring in human SCI, we used the Fejota
TM clip com-
pression model of SCI in vivo in lpr and Wt mice at
8 weeks. Consistent with previous ﬁnding in our own
research and that of others, there was a signiﬁcantly
reduced level of caspase-3 and 9 activation following SCI
in lpr mice relative to Wt mice [11]. In the present study,
we present new ﬁndings showing a reduction of GFAP,
iba1, NF-jB and p-IKappaB expression and activated
microglia in the injury epicenter and decreased neurolog-
ical dysfunction following SCI in lpr mice relative to Wt
mice. These results suggest that Fas has the potential to
reduce the extent of secondary damage by interacting with
microglia and leukocytes in the following ways: (1)
inhibiting microglia activation thereby reducing pro-
inﬂammatory cytokine production resulting in restricted
neutrophil inﬁltration and suppressed inﬂammatory
responses. (2) inhibiting GFAP expression which promotes
axonal regeneration as we found a signiﬁcant increase in
levels of NF200 and b-III tubulin and improved neuro-
logical function recovery in lpr mice relative to Wt mice
following SCI. (3) increasing MMP-2 promoted functional
recovery after injury by regulating the formation of glial
scarring and whitematter sparing and/or axonal plasticity
[23]. These ﬁndings provide a better understanding of the
inﬂammatory mechanisms after SCI. The results further
suggest that neutralization of Fas reduces the initial inﬁl-
tration of inﬂammatory cells and apoptosis, creating an
inﬂammatory response that facilitates recovery of loco-
motor function after SCI. There are conﬂicting results
relating to the lack of Fas on CNS resident neural cells
reducing apoptosis and improving neurological function
recovery in lpr mice following SCI. We [11] and others
[44] have shown that Fas deﬁciency and competitive
inhibition of Fas activation [1] can reduce apoptosis [45]
and promote neurobehavioral recovery in animal models of
SCI. In contrast, Letellier et al. [31] reported that Fas
deﬁcient mice do not show decreased caspase-3 activity or
improved functional recovery following SCI. There are
several factors contributing to these conﬂicting results in
lpr mice following SCI. First, Letellier et al. [31] used Fas-
ﬂoxed mice with a Nestin-Cre background at 17.5 weeks.
lpr mice develop a lymphoproliferative disorder at ages
greater than 18 weeks. In contrast, we used B6.MRL-Fas-
lpr mice with a C57Bl/6 J background at 8 weeks of age to
avoid this potentially confounding feature, which develops
later and less severely in this strain [42]. Second, we used a
different model of SCI to Letellier which could contribute
to differing results.
Pro-inﬂammatory cytokines/chemokines are strongly
implicated in regulating neutrophil inﬁltration [18]. Lac-
roix reported that enhanced IL-6 signaling after SCI results
in a sixfold increase in neutrophil inﬁltration and expanded
the neural damaged area [30]. The administration of a
mixture of pro-inﬂammatory cytokines (IL-1b, IL-6. and
TNFa) at the acute phase of SCI has been shown to pro-
voke an increase in the recruitment of leukocytes to the
lesion site [29]. The rise of cytokines is transient from
15 min to 5 days as levels return to base level after spinal
cord injury in rats, humans and mice thus establishing the
fact that a short lived burst of inﬂammatory cytokines is a
feature of SCI across several species [29, 36, 40]. A sys-
tematic study that documents the acute and chronic
evolution of families of inﬂammatory molecules is lacking.
In the present study, to test the release of pro-inﬂammatory
mediator (cytokines and chemokines) as regulators of the
inﬁltration of leukocytes and macrophages into the injured
spinal cord, we analyzed the release of cytokines and
chemokines in sham controls, 3, 14 and 70 days following
SCI in lpr and Wt mice. We ﬁrst reported on 32 cytokine
and chemokines derived from same sample and from dif-
ferent time points following SCI in both lpr and Wt mice.
Importantly, we show a signiﬁcant increase of inﬂamma-
tory mediators: cytokines (IL-1alpha, IL-12p40, IL-7 and
IL-15 at 14 days and IL-7 and IL-13 at 70 days) in Wt
mice after SCI. The rise of chemokines lasts even longer
than that of cytokines from 3 to 70 days after spinal cord
injury in both lpr and Wt mice. Our results show reduced
chemokine expression and increased anti-inﬂammatory
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123cytokines IL-10 may be contributing to better BMS score
in lpr mice than Wt mice following SCI. These ﬁndings are
consistent with Bethea [8] who reported that systemically
administered interleukin-10 reduces tumor necrosis factor-a ˛
production signiﬁcantly improves functional recovery fol-
lowing traumatic SCI in rats.
In conclusion, we report novel evidence showing that
Fas/FasL-mediated apoptosis of neurons and oligodendro-
cytes and inﬂammation contributes to the pathobiology of
spinal cord degeneration and affects neuronal function and
survival in human SCI. Fas-deﬁcient mice exhibit signiﬁ-
cantly reduced inﬁltration of inﬂammatory cells (microglia/
macrophages), the level of GFAP and p-IKappaB expres-
sion and release of cytokines and chemokines which
facilitates recovery of locomotor function when compared
with Wt mice following SCI. This work provides a com-
pelling rationale for therapeutically targeting Fas in human
SCI.
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